Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Giral

Showing results (21-30 of 133) with videos related to

Pageof 14
Sort By:
European Heart Journal|July 31, 2019
Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in FrancePhilippe Giral, Anke Neumann, Alain Weill, et al.
European Heart Journal|March 14, 2013
The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITERM John Chapman, Philippe Giral, Philip J Barter
Chest|December 13, 2016
Introducing High-Sensitivity Cardiac Troponin T as a Biomarker of OSA-Related Cardiovascular Morbidity in Obesity Hypoventilation SyndromeDenis Monneret, Philippe Giral, Dominique Bonnefont-Rousselot, et al.
Hepatology (Baltimore, Md.)|August 21, 2018
Relationship Among Fatty Liver, Specific and Multiple-Site Atherosclerosis, and 10-Year Framingham ScoreRaluca Pais, Alban Redheuil, Philippe Cluzel, et al.
Presse Medicale (Paris, France : 1983)|December 11, 2007
[Ten-year morbidity and mortality in a cohort of dyslipidemic patients seen at a hospital endocrinology department]Valérie Carreau, Eric Bruckert, Dominique Bonnefont-Rousselot, et al.
Journal of Clinical Lipidology|March 26, 2018
Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETPM John Chapman, Alexina Orsoni, Paul Robillard, et al.
Pharmacology & Therapeutics|February 16, 2010
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular riskM John Chapman, Jan S Redfern, Mark E McGovern, et al.
Current Opinion in Cardiology|July 7, 2011
Optimal pharmacotherapy to combat the atherogenic lipid triadM John Chapman, Jan S Redfern, Mark E McGovern, et al.
The American Journal of Clinical Hypnosis|January 23, 2023
Psychosocial effects of hypnosis in patients with obesity: a pilot randomized controlled trialAurélie Untas, Kristopher Lamore, Fabienne Delestre, et al.
Cardiovascular Drugs and Therapy|April 27, 2004
A comprehensive description of muscle symptoms associated with lipid-lowering drugsSylvia Franc, Sylvie Dejager, Eric Bruckert, et al.
Pageof 14

Showing results (21-30 of 133) with videos related to

Sort By:
Pageof 14
European Heart Journal|July 31, 2019
Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in FrancePhilippe Giral, Anke Neumann, Alain Weill, et al.
European Heart Journal|March 14, 2013
The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITERM John Chapman, Philippe Giral, Philip J Barter
Chest|December 13, 2016
Introducing High-Sensitivity Cardiac Troponin T as a Biomarker of OSA-Related Cardiovascular Morbidity in Obesity Hypoventilation SyndromeDenis Monneret, Philippe Giral, Dominique Bonnefont-Rousselot, et al.
Hepatology (Baltimore, Md.)|August 21, 2018
Relationship Among Fatty Liver, Specific and Multiple-Site Atherosclerosis, and 10-Year Framingham ScoreRaluca Pais, Alban Redheuil, Philippe Cluzel, et al.
Presse Medicale (Paris, France : 1983)|December 11, 2007
[Ten-year morbidity and mortality in a cohort of dyslipidemic patients seen at a hospital endocrinology department]Valérie Carreau, Eric Bruckert, Dominique Bonnefont-Rousselot, et al.
Journal of Clinical Lipidology|March 26, 2018
Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETPM John Chapman, Alexina Orsoni, Paul Robillard, et al.
Pharmacology & Therapeutics|February 16, 2010
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular riskM John Chapman, Jan S Redfern, Mark E McGovern, et al.
Current Opinion in Cardiology|July 7, 2011
Optimal pharmacotherapy to combat the atherogenic lipid triadM John Chapman, Jan S Redfern, Mark E McGovern, et al.
The American Journal of Clinical Hypnosis|January 23, 2023
Psychosocial effects of hypnosis in patients with obesity: a pilot randomized controlled trialAurélie Untas, Kristopher Lamore, Fabienne Delestre, et al.
Cardiovascular Drugs and Therapy|April 27, 2004
A comprehensive description of muscle symptoms associated with lipid-lowering drugsSylvia Franc, Sylvie Dejager, Eric Bruckert, et al.
Pageof 14